Difference between revisions of "Taloporfin (Laserphyrin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
m |
||
| Line 7: | Line 7: | ||
*2015-05-26: New additional indication for the treatment of recurrent [[esophageal cancer]] associated with local persistence after chemoradiotherapy or radiotherapy. | *2015-05-26: New additional indication for the treatment of recurrent [[esophageal cancer]] associated with local persistence after chemoradiotherapy or radiotherapy. | ||
| + | ==Also known as== | ||
| + | *'''Brand name:''' Laserphyrin | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Latest revision as of 23:53, 31 July 2023
Photosensitizer
Diseases for which it is used
History of changes in PMDA indication
- 2013-09-20: New additional indication and a new dosage for the treatment of primary malignant brain tumor (only for the case where surgical excision of tumor is performed).
- 2015-05-26: New additional indication for the treatment of recurrent esophageal cancer associated with local persistence after chemoradiotherapy or radiotherapy.
Also known as
- Brand name: Laserphyrin